Ezdinli E Z, O'Sullivan D D, Wasser L P, Kim U, Stutzman L
JAMA. 1979 Jul 20;242(3):258-60.
Autopsy examinations were conducted in 72 patients with hematologic malignant neoplasms who received antibacterial therapy before their deaths. These patients were participants in a large double-blind study designed to assess the efficacy of oral amphotericin B in decreasing the incidence of candidal infection. The patients received either 50 mg of amphotericin B orally four times a day, or they received a matching placebo. Eight of 33 patients (24%) who had received placebo and two of 39 (5%) who had received amphotericin had histopathologic evidence of disseminated candidiasis. We conclude that in these patients with hematologic malignant neoplasms who received antibiotics within two weeks of death, the concomitant oral administration of amphotericin was effective in decreasing the incidence of systemic candidal infections, indicating that the gastrointestinal tract serves as a portal of entry for Candida albicans.
对72例血液系统恶性肿瘤患者进行了尸检，这些患者在死亡前接受了抗菌治疗。这些患者参与了一项大型双盲研究，旨在评估口服两性霉素B降低念珠菌感染发生率的疗效。患者要么每天口服4次50毫克两性霉素B，要么接受匹配的安慰剂。接受安慰剂的33例患者中有8例（24%）以及接受两性霉素的39例患者中有2例（5%）有播散性念珠菌病的组织病理学证据。我们得出结论，在这些在死亡前两周内接受抗生素治疗的血液系统恶性肿瘤患者中，同时口服两性霉素可有效降低系统性念珠菌感染的发生率，这表明胃肠道是白色念珠菌的一个入口。
